Pre-operative Immunotherapy Combination Strategies in Breast Cancer
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
International, open label, window of opportunity phase II trial that aims to evaluate the
effects of immunotherapy based treatment combinations in women with untreated, histologically
confirmed, operable, ER+, HER2-negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Queen Mary University of London
Collaborators:
Asan Medical Center Hoffmann-La Roche Kliniken Essen-Mitte MedSIR